









| Last update : Dicembre 2007 |  |  |  |  |  |  |  |  |
|--------------------------------|--|--|---|--|---|---|---|---|
| Company | Baxter | Baxter | Baxter | Biotest Pharma GmbH | CSL-Behring | CSL-Behring | Kedrion | Grifols |
| Name of product | Gammagard S/D | Endobulin S/D | SUBCUVIA | Intraglobin® F | Sandoglobulin (Iyo) | Vivaglobin | IG VENA | Flebogamma |
| Available for Hospital therapy | Yes | Yes | Yes | Yes | Registered | Registered | Yes | Yes |
| Available for Home therapy | May vary in different countries due to different licensing situations. | May vary in different countries due to different licensing situations. | Yes | not available for home therapy | - | Yes | None | |
| IVIg, SCiG or IMiG | IVIg | IVIg | SCiG | IVIg | IVIg | SCiG | IVIg | IVIg |
| Patient's age | All ages | All ages | Adults and juveniles at the age of ≥ 12 years | unlimited | Adults and children | Adults and children | Adults & Children | |
| Présentation | Lyophilised Powder | Lyophilised Powder | Liquid | ready-to-use solution | Lyophilisat | Liquid | Liquid | Liquid |
| Concentration % | 5% or 10% | 5% | 16% | 5% solution | 3%, 6%, 9%, 12% | 16% | 5% | 5% |
| Content of IgG | ≥ 90% | 95% immunoglobulin | ≥ 90% | ≥ 95% | ≥ 96% | IgG monomers & dimers 97-97% • IgG polymers 3-5% | 95% | ≥ 99% |
| IgG1 | 63% | 50-80% | 45-75% | 62% | 60.7% | 61% | 24,3 - 37,2 mg | 70.3% |
| IgG2 | 21,80% | 20-50% | 20-45% | 34% | 31.9% | 28% | 12,4 - 22,1 mg | 24.7% |
| IgG3 | 5,40% | < 0.5% | 3-10% | 0.5% | 3.8% | 5% | 0,9 - 1,5 mg | 3.1% |
| IgG4 | 0,20% | 1-3% | 2-8% | 3.5% | 3.6% | 6% | 0,1 - 0,5 mg | 2% |
| Content of IgA | ≤ 3 µg/ml | ≤ 0.05 mg/ml | ≤ 4.8 mg/ml | ≤ 2.5 mg/ml | 1.2g/L (typical value) | max. 1.7 g/L | < 0,05 mg/ml | <0,05 mg/ml |
| Glucose, Maltose,... | Glucose | ENDOBLIN S/D contains 1 gram of glucose per gram of immunoglobulin G. | Glycine | glucose 25 mg | Sucrose | Glycine | Maltose | |
| Average dosage for PID | The dosage regimen should achieve a trough level of 4-6 g/l. The dose and dosage regimen may need to be individualised depending on pharmacokinetic and clinical response (Also see European core SPC). | The dosage regimen should achieve a trough level of 4-6 g/l. • The dose and dosage regimen may need to be individualised depending on pharmacokinetic and clinical response (Also see European core SPC). | The dosage should be adjusted to maintain an approximate level of at least 4-6 g/l of circulating IgG. • The dose and dosage regimen may need to be individualised depending on pharmacokinetic and clinical response | initial 0.4 - 0.8 g/kg, followed by 0.2 -0.8 g/kg | 0.2-0.8g/kg bodyweight | 0.2-0.8g/kg bodyweight | 0,4 - 0,8 g/kg | |
| Max. Speed of infusion | Gammagard S/D should be infused at an initial rate of 0.5 ml/kg BW/hour. If well tolerated, the rate of administration may gradually be increased to a maximum of 4 ml/kg BW/hour. Patients who tolerate Gammagard S/D 5% solutions at 4 ml/kg BW/hour can be infused with the 10% concentration starting at 0.5 ml/kg BW/hour. If no adverse events occur, the rate can be increased gradually up to a maximum rate of 8 ml/kg BW/hour. | During the first 30 minutes, Endobulin S/D is administered at an initial rate of 0.5 ml/kg BW/hour. If well tolerated, the rate of administration may gradually be increased to a maximum of approx. 8 ml/kg BW/hour for the remainder of the infusion. In adults, if well tolerated, the rates of subsequent infusions may be increased to a maximum of 15 ml/kg BW/hour. | It is recommended to use an initial administration speed of 10 ml/h/pump. The infusion speed can be enhanced for 1 ml/h/ pump every subsequent infusion. The recommended maximum speed is 20 ml/h/pump. More than 1 pump can be used simultaneously. | 2.2 mg/ml per hour | About 2.5ml/min | About 22ml/hour | 40 drops/minute | |
| Intervals of infusion for PID | See European core SPC | See European core SPC | After the loading dose, maintenance doses at repeated intervals to reach a cumulative monthly dose of 0.4-0.8 g/kg | dependent on the individual serum IgG level between 2 and 4 weeks | Usually every 2-4 weeks | usually weekly | 21-28 days | |
| Preserving | • Do not store above 25°C. • Do not freeze, the solvent vial might break. • Keep vial in the outer carton to protect from light. | • Store in a refrigerator (2°C - 8°C) • Do not freeze, the solvent vial might break • Keep vial in the outer carton in order to protect from light | • Store in a refrigerator (2°C - 8°C) • The packaged product may be kept at room temperature (up to 25°C) for up to 6 weeks. In this case, the product expires at the end of the 6 weeks period. • Do not freeze • Keep the vial in the carton to protect from light. | storage in refrigerator (+2 to +8 °C) - shelf-life: 2 years | 3 years ≤25°C | 3 years | +2°C < T < +8°C | Between +2°C and +25°C. Do not freeze. Discard after expiration date. |
| Time for reconstitution | General information not available. | General information not available. | N/A | | A few minutes | none | Ready for use | none |
| Packaging* | Pack sizes of 0.5g, 2.5g, 5g, and 10g of lyophilized Gammagard S/D per vial, with appropriate volume of water for injections. Each pack also contains devices for reconstitution and administration. | Pack sizes of 0.5g, 1g, 2.5g, 5g and 10g of lyophilized Endobulin S/D per vial with appropriate volume of water for injections. • Each pack also contains devices for reconstitution and administration. | Pack sizes of 1 x 5 ml, 20 x 5 ml, 1 x 10 ml, and 20 x 10 ml. | containers with 20, 50, 100 or 200 ml | 1g, 3g, 6g, 12g | 10ml, 20ml | 1g/ 20 ml ; 2,5 g/ 50 ml ; 5 g/ 100 ml ; 10 g/ 200 ml | |

* May be different from country to country